8-K: Blade Air Mobility Achieves Record Medical Revenue in Q1 2024, Reaffirms Profitability Guidance

Blade Air Mobility reported record-high medical revenue and improved profitability in the first quarter of 2024, driven by strong growth in its medical transport business.

Summary

• Blade Air Mobility announced its financial results for the first quarter ended March 31, 2024, showcasing significant growth in its medical transport segment.
• The company achieved a record-high medical revenue of $36.0 million, a 34.6% increase year-over-year and a 12.6% sequential increase compared to the previous quarter.
• Net loss improved to $(4.2) million, a $6.0 million improvement compared to the same period last year.
• Adjusted EBITDA also improved to $(3.5) million, a $4.2 million improvement year-over-year.
• The Medical segment's Adjusted EBITDA reached a record $4.4 million, a 134.5% increase year-over-year.
• Total revenue increased by 13.8% to $51.5 million compared to $45.3 million in the prior year period.
• Excluding the impact of discontinuing the scheduled jet service between New York and South Florida, total revenue increased by 21.5% year-over-year.
• The company reaffirmed its guidance for positive Adjusted EBITDA in full-year 2024 and double-digit millions in 2025.
• Blade closed on seven of the eight previously announced jet aircraft acquisitions since quarter end.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong growth in the medical segment, significant improvements in profitability metrics, and reaffirmed guidance. While there are some challenges in the passenger segment, the overall tone is optimistic and suggests a positive trajectory for the company.

Positives

• The Medical business achieved record revenue and Adjusted EBITDA, driven by increased trip volumes and distances.
• The company is seeing margin improvements in the Medical business due to dedicated aircraft and improved economies of scale.
• The Medical sales pipeline is strong, with expectations for continued new client onboarding.
• The New York Airport transfer business showed continued year-over-year growth with a third consecutive quarter of positive Flight Profit contribution.
• The company ended the quarter with $151.0 million in cash and short-term investments.
• Adjusted SG&A as a percentage of revenue decreased by 630 bps year-over-year.

Negatives

• The Short Distance revenue decreased by 5.9% due to inclement weather in Europe and lower passenger volume in Canada.
• Jet and Other revenue decreased by 29.7% due to the discontinuation of the BladeOne service between New York and South Florida, although excluding this, it increased 9.4% year-over-year.
• The company is still reporting a net loss and negative Adjusted EBITDA, although both have improved significantly year-over-year.
• Capital expenditures of $1.1 million were incurred primarily for new office space and software development.

Risks

• The company's future performance is subject to risks including continued losses, market growth, competition, and reliance on third-party operators.
• Adverse publicity from accidents involving small aircraft or helicopters could negatively impact the company.
• Changes in consumer preferences, economic conditions, and regulatory environments could affect the company's performance.
• The company's ability to access additional funding and manage growth are also potential risks.
• The company is exposed to risks related to climate change, natural disasters, and pandemics.

Future Outlook

The company reaffirmed its guidance for positive Adjusted EBITDA in full-year 2024 and double-digit millions in 2025, with expected double-digit year-over-year revenue growth in 2025.

Management Comments

• Rob Wiesenthal, Blade's CEO, stated that this was the best quarter in company history for the Medical business.
• Rob Wiesenthal also mentioned that the Medical sales pipeline is strong and they expect continued new client onboarding.
• Will Heyburn, Blade's CFO, noted that the key driver of the path to positive Adjusted EBITDA is margin improvement in the Medical business.
• Melissa Tomkiel, Blade's President, highlighted the cash flow benefits from strategic aircraft ownership in high-density markets.

Industry Context

This announcement reflects a growing trend in the air mobility sector, particularly in the medical transport space, where companies are leveraging technology and strategic partnerships to improve efficiency and profitability. Blade's focus on asset-light models and strategic aircraft ownership aligns with industry trends towards cost-effective and flexible operations.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, Blade's 34.6% year-over-year growth in medical revenue is significant, suggesting a strong position in the medical air transport market.
• Companies like Air Methods and Med-Trans Corporation are major players in the medical transport industry, and Blade's growth indicates it is gaining market share.
• Blade's focus on urban air mobility and its transition to electric vertical aircraft (EVA) positions it to compete with companies like Joby Aviation and Archer Aviation in the long term, although these companies are not directly comparable in the short term.
• The improvement in Adjusted EBITDA and Flight Margin suggests that Blade is making progress towards profitability, which is a key metric for investors in the air mobility sector.

Stakeholder Impact

• Shareholders will likely view the improved financial results and reaffirmed guidance positively.
• Employees may benefit from the company's growth and improved financial stability.
• Customers in the medical sector will benefit from the company's expanded services and capabilities.
• Suppliers and creditors may see the company as a more reliable partner due to its improved financial performance.

Next Steps

• The company expects to close on the remaining jet aircraft acquisition in the coming months.
• Blade anticipates continued new client onboarding in the Medical segment throughout the year.
• The company will continue to focus on margin improvement in the Medical business.
• Blade will continue to grow its New York Airport transfer business.

Key Dates

Keywords

Medical Transport, Air Mobility, Adjusted EBITDA, Flight Profit, Organ Transport, Helicopter Services, Financial Results, Revenue Growth, Profitability, Blade Air Mobility